Skip to main content

FY2023 Consolidated Financial Overview

[Based on Japanese GAAP]

Operating Results

Operating Results Summary

  • Net sales

    62,843 million yen

    YOY 3.9%

  • Operating profit

    6,500 million yen

    YOY 27.3%

  • Ordinary profit

    6,522 million yen

    YOY 24.6%

  • Profit attributable to owners of parent

    7,545 million yen

    YOY 78.0%

  • Earnings per share

    266.51 yen

    YOY 77.6%

The Group’s net sales in the consolidated fiscal year under review were 62,843 million yen, up 2,381 million yen year on year (YoY). This was due mainly to growth in the pharmaceutical business driven by the growth in obstetrics and gynecological products. Cost of sales was 32,178 million yen, and cost of sales ratio was down 1.5% YoY, resulting in an increase of 2,079 million yen in gross profit YoY to 30,664 million yen. At the same time, selling, general and administrative expenses rose by 687 million yen YoY to 24,164 million yen. As a result, operating profit was up 1,392 million yen YoY to 6,500 million yen, for a ratio of operating profit to net sales of 10.3%. Ordinary profit was 6,522 million yen, after recording 414 million yen in non-operating income and 392 million yen in non-operating expenses. While the Company recorded 3,340 million yen during the period in extraordinary income associated with sale of investment securities, profit attributable to owners of parent was up 3,307 million yen YoY to 7,545 million yen.

In addition, ASKA Pharmaceutical Co., Ltd. a subsidiary of the Company, has executed a capital increase agreement to issue new shares of its equity method affiliate, Ha Tay Pharmaceutical Joint Stock Company, with the aim of strengthening the partnership between the two companies.

Segment

Net sales

(Millions of yen)

Segment name 1Q 2Q 3Q Full year
Pharmaceutical business 14,420 28,404 43,603 56,016
Animal Health business 1,560 3,162 5,096 6,664
Others 42 80 124 162

(i) Pharmaceutical business

The pharmaceutical business, which focuses on the three fields: internal medicine, obstetrics and gynecology, and urology, showed favorable trends overall, despite the impact of the periodical NHI drug price revisions. A look at results by product shows that the results in the field of obstetrics and gynecology were driven by the large-scale growth in the uterine fibroid and endometriosis agent RELUMINA (relugolix), to 9,906 million yen (up 12.1% YoY), and the dysmenorrhea agent DroEthi (drospirenone/ ethinylestradiol), which went on sale in June 2022, largely drove performance with sales of 6,125 million yen (up 66.3% YoY). Sales also grew in the internal medicine area, as sales of the thyroid hormone agent THYRADIN (levothyroxine), our main product in this field, grew to 7,862 million yen (up 1.7% YoY) and those of the poorly absorbable rifamycin antimicrobial agent RIFXIMA (rifaximin) to 5,864 million yen (up 8.7% YoY). In the urology field, sales of the LH-RH derivative microcapsule sustained-release agent LEUPRORELIN (leuprorelin) were 4,430 million yen (down 11.4% YoY).

As a result of the above factors, the segment sales were 56,016 million yen (up 4.5% YoY), and segment profit was 7,647 million yen (up 32.3% YoY).

(ii) Animal health business

Sales of the animal health business, which sells products such as veterinary pharmaceuticals and feed additives, were 6,664 million yen (up 0.0% YoY). However, the segment profit was 195 million yen (down 52.3% YoY) due to rising costs of raw materials and other items.

(iii) Other businesses

Sales of other businesses, which include clinical testing, medical devices, were 162 million yen (down 26.3% YoY). Segment loss was 125 million yen (vs. a loss of 6 million yen in the same period of the previous year).

Financial Position

Financial Position Summary

  • Total assets

    90,745 million yen

    YOY 4.1%

  • Net assets

    61,930 million yen

    YOY 13.6%

  • Equity ratio

    68.2 %

    YOY 5.6point

Overview of Financial Position

(Assets)

Total assets at the end of the consolidated fiscal year under review stood at 90,745 million yen, up 3,607 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to increases in merchandise and finished goods, and investment securities, despite a decrease in distributorship.

(Liabilities)

Total liabilities at the end of the consolidated fiscal year under review stood at 28,815 million yen, down 3,789 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to decreases in retirement benefit liability and long-term borrowings (including current portion of long-term borrowings).

(Net assets)

Total assets at the end of the consolidated fiscal year under review stood at 61,930 million yen, up 7,396 million yen from the end of the consolidated fiscal previous year. This figure was due primarily to an increase in retained earnings resulting from the recording of profit attributable to owners of parent.

The resulting equity ratio was 68.2%, up 5.6 percentage points from the end of the previous consolidated fiscal year.

Cash Flow Summary

  • Cash flows from operating activities

    1,486 million yen

  • Cash flows from investing activities

    1,706 million yen

  • Cash flows from financing activities

    (3,943) million yen

  • Cash and cash equivalents at end of period

    16,738 million yen

Overview of Cash Flow Position

The balance of cash and cash equivalents at the end of the current consolidated fiscal year stood at 16,738 million yen, down 766 million yen from the end of the previous consolidated fiscal year.

(Cash flows from operating activities)

Net cash provided by operating activities was 1,486 million yen (vs. a gain of 3,351 million yen in the same period of the previous year), due mainly to the recording of profit before income taxes, despite a decrease in retirement benefit liability.

(Cash flows from investing activities)

Net cash provided by investing activities was 1,706 million yen (vs. a loss of 1,126 million yen in the same period of the previous year). This was due mainly to sales of investment securities.

(Cash flows from financing activities)

Net cash used in financing activities was 3,943 million yen (vs. a loss of 1,820 million yen in the same period of the previous year). This was due mainly to repayments of long-term borrowings.